Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
VPM-1002 by Serum Institute of India for Transitional Cell Carcinoma (Urothelial Cell Carcinoma): Likelihood of Approval
VPM-1002 is under clinical development by Serum Institute of India and currently in Phase II for Transitional Cell Carcinoma (Urothelial...
Data Insights
VPM-1002 by Serum Institute of India for Muscle Invasive Bladder Cancer (MIBC): Likelihood of Approval
VPM-1002 is under clinical development by Serum Institute of India and currently in Phase II for Muscle Invasive Bladder Cancer...